• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Study peers into ocular waste recycling


A team of researchers has uncovered a mechanism that causes blindness, could lead to targeted therapies.

Modern microscope and human tissue section slide with computer monitor show glandular image.(Image Credit: AdobeStock/arcyto)

Retinal is a derivative of vitamin A, which is found in foods such as leafy green vegetables. (Image Credit: AdobeStock/arcyto)

A team of researchers has unlocked the key to a protein that commonly causes blindness.

According to a study in the Journal of Biological Chemistry,1 the biological process involves a protein that is essential for transporting toxic compounds out of the eye, similar to a garbage recycling service. The challenge is that, like food and the waste it generates, these compounds are essential for the eye to function properly — until they build up and cause blindness.

According to a news release from the American Society of Biochemistry and Molecular Biology (ASBMB), the scientists behind the study researched a protein transporter, called ABCA4, that lines the edges of specialized photoreceptor cells in the retina and is normally poised to remove toxic, fatty retinal byproducts called N-Ret-PE. Retinal is a derivative of vitamin A, which is found in foods such as leafy green vegetables.

“Retinal is critical for vision,” Robert Molday, a professor of biochemistry and molecular biology at the University of British Columbia who oversaw the work, said in the release. “But, it's also potentially very toxic because it has a very reactive element. So, cells have to be able to balance between using retinal for sustained vision as well as managing its toxicity .”

Mutations in ABCA4 can cause N-Ret-PE buildup, which leads to vision loss in diseases such as Stargardt disease, the most common inherited form of macular degeneration, and affects approximately 30,000 people nationwide. There is currently no therapy or cure for the disease.

According to the news release, the researchers were interested in finding out how the ABCA4 transporter malfunctions to cause vision loss. They found that a portion of the protein that interacts with N-Ret-PE, known as the binding pocket, is inert in some patients with Stargardt disease. Therefore, the toxic compounds slip out of the ABCA4 transporter and cannot be removed from the retina.

Next, by changing the makeup of ABCA4, the researchers showed they could mimic the effect of the Stargardt mutations.

“We were able to elucidate the mechanism of binding, which paves the way for treatments for Stargardt disease,” Tongzhou Xu, a postdoctoral fellow at UBC and lead author of the study, said in the release.

Moreover, the research team noted in the news release it is optimistic that one day there will be a targeted therapeutic for patients with Stargardt disease that may use gene therapy and specialized particles for delivery to the eye. Gene therapy approaches have already been successfully used to correct mutations in a similar transporter, which causes cystic fibrosis.

“We are now applying two types of technologies to alter ABCA4,” Molday concluded in the news release. “One which was developed to specifically correct the DNA with gene-editing approaches. We are coupling that with lipid nanoparticles, which have been used in the COVID-19 vaccine to encapsulate mRNA. So, by combining these two technologies, we envision being able to potentially correct the defects in individuals with Stargardt's disease that have specific point mutations.”

1. Tongzhou Xu, Laurie L. Molday, Robert S. Molday. Retinal-phospholipid Schiff-base conjugates and their interaction with ABCA4, the ABC transporter associated with Stargardt Disease. Journal of Biological Chemistry. Published March 15, 2023. Doi: 10.1016/j.bc.2023.104614.
Related Videos
Jay Barth, MD
Moving beyond the drop: CEO provides updates on Oyster Point's pipeline
Stargardt research: Therapy on the horizon for inherited retinal disease
© 2024 MJH Life Sciences

All rights reserved.